Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'
Clicks: 215
ID: 273575
2021
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
30.4
/100
215 views
27 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #8 of 31 articles by views in esmo open
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Applying both versions of the ESMO-MCBS can help to identify potentially beneficial cancer indications, but also those with rather uncertain or low clinical benefit and thus, support the fair allocation of limited health care resources.
| Reference Key |
n2021esmotwelve
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Grössmann N;Wolf S;Rothschedl E;Wild C;; |
| Journal | esmo open |
| Year | 2021 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
humans
pubmed abstract
nih
national institutes of health
national library of medicine
drug approval
pmid:34087744
pmc8182388
doi:10.1016/j.esmoop.2021.100166
n grössmann
s wolf
c wild
antineoplastic agents* / therapeutic use
medical oncology
neoplasms* / drug therapy
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.